Intra-rectal use of epinephrine in radiotherapy of prostate cancer
Received 10 September 2018
Accepted for publication 10 April 2019
Published 27 May 2019 Volume 2019:11 Pages 4847—4854
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 5
Editor who approved publication: Dr Antonella D'Anneo
Shang-Bin Qin,1 Xian-Shu Gao,1 Hong-Zhen Li,1 Chao-Xing Liu,2 Dong-Liang Hou,3 Wei-Dong Nian,4 Xue-Ying Li,5 Dian Wang6
1Department of Radiation Oncology, Peking University First Hospital, Beijing, People’s Republic of China; 2Department of Radiation Oncology, Shijiazhuang City First Hospital, Shijiazhuang, People’s Republic of China; 3Department of Radiation Oncology, Beijing Shijitan Hospital, Beijing, People’s Republic of China; 4Department of General Surgery, Peking University First Hospital, Beijing, People’s Republic of China; 5Department of Medical Statistics, Peking University First Hospital, Beijing, People’s Republic of China; 6Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA
Purpose: The aim of the study was to evaluate the feasibility and toxicity of intra-rectal epinephrine during prostatic radiotherapy.
Materials and methods: A total of 34 patients with prostate cancer were randomized to receive daily intra-rectal epinephrine (4 mg in 40 mL, n=16) or placebo (40 mL normal saline, n=18) 5 min before daily radiotherapy. Physical examination including systolic blood pressure (SBP) and heart rate (HR) was performed before, 5 min after, and 20 min after intra-rectal use. Toxicities were graded using the Radiation Therapy Oncology Group standard. A two-sided Fisher’s exact test was used to compare proportions between groups. A mixed-effects model was used to analyze multiple measurements of SBP and HR. Survival curves were calculated using the Kaplan–Meier method and compared between groups using the log-rank test.
Results: All patients completed the protocol treatment and reported no cardiovascular symptoms after intra-rectal administration. There were no differences in SBP and HR between these two groups at any time point (before, 5 min after, and 20 min after epinephrine). At 5 weeks after the start of radiotherapy, the incidence of rectal toxicity≥grade 2 was 27.8% (5/18) for the control group versus 12.5% (2/16) for the epinephrine group, but was not statistically significant (p=0.4). There was no rectal toxicity≥grade 2 in these two groups beyond 2-year follow-up. The 5-year biochemical relapse-free survival was 75.0% and 72.2% for the epinephrine and control group, respectively.
Conclusion: Results of this pilot randomized trial have demonstrated that intra-rectal administration of epinephrine is feasible and safe in prostatic radiotherapy. Its radio-protective effect warrants further investigation.
Keywords: radiation proctitis, epinephrine, radiotherapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]